These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
45. 2-(4-Hydroxy-3-methoxyphenyl)-benzothiazole suppresses tumor progression and metastatic potential of breast cancer cells by inducing ubiquitin ligase CHIP. Hiyoshi H; Goto N; Tsuchiya M; Iida K; Nakajima Y; Hirata N; Kanda Y; Nagasawa K; Yanagisawa J Sci Rep; 2014 Nov; 4():7095. PubMed ID: 25403352 [TBL] [Abstract][Full Text] [Related]
46. Elimination of ALDH+ breast tumor initiating cells by docosahexanoic acid and/or gamma tocotrienol through SHP-1 inhibition of Stat3 signaling. Xiong A; Yu W; Liu Y; Sanders BG; Kline K Mol Carcinog; 2016 May; 55(5):420-30. PubMed ID: 25648304 [TBL] [Abstract][Full Text] [Related]
47. Next generation sequencing of triple negative breast cancer to find predictors for chemotherapy response. Lips EH; Michaut M; Hoogstraat M; Mulder L; Besselink NJ; Koudijs MJ; Cuppen E; Voest EE; Bernards R; Nederlof PM; Wesseling J; Rodenhuis S; Wessels LF; Breast Cancer Res; 2015 Oct; 17(1):134. PubMed ID: 26433948 [TBL] [Abstract][Full Text] [Related]
48. Arctigenin inhibits STAT3 and exhibits anticancer potential in human triple-negative breast cancer therapy. Feng T; Cao W; Shen W; Zhang L; Gu X; Guo Y; Tsai HI; Liu X; Li J; Zhang J; Li S; Wu F; Liu Y Oncotarget; 2017 Jan; 8(1):329-344. PubMed ID: 27861147 [TBL] [Abstract][Full Text] [Related]
49. Molecular profiling of the residual disease of triple-negative breast cancers after neoadjuvant chemotherapy identifies actionable therapeutic targets. Balko JM; Giltnane JM; Wang K; Schwarz LJ; Young CD; Cook RS; Owens P; Sanders ME; Kuba MG; Sánchez V; Kurupi R; Moore PD; Pinto JA; Doimi FD; Gómez H; Horiuchi D; Goga A; Lehmann BD; Bauer JA; Pietenpol JA; Ross JS; Palmer GA; Yelensky R; Cronin M; Miller VA; Stephens PJ; Arteaga CL Cancer Discov; 2014 Feb; 4(2):232-45. PubMed ID: 24356096 [TBL] [Abstract][Full Text] [Related]
50. Chloroquine eliminates cancer stem cells through deregulation of Jak2 and DNMT1. Choi DS; Blanco E; Kim YS; Rodriguez AA; Zhao H; Huang TH; Chen CL; Jin G; Landis MD; Burey LA; Qian W; Granados SM; Dave B; Wong HH; Ferrari M; Wong ST; Chang JC Stem Cells; 2014 Sep; 32(9):2309-23. PubMed ID: 24809620 [TBL] [Abstract][Full Text] [Related]
51. Targeting the Janus-activated kinase-2-STAT3 signalling pathway in pancreatic cancer using the HSP90 inhibitor ganetespib. Nagaraju GP; Mezina A; Shaib WL; Landry J; El-Rayes BF Eur J Cancer; 2016 Jan; 52():109-19. PubMed ID: 26682870 [TBL] [Abstract][Full Text] [Related]
52. JAK2 tyrosine kinase inhibitor AG490 suppresses cell growth and invasion of gallbladder cancer cells via inhibition of JAK2/STAT3 signaling. Fu LX; Lian QW; Pan JD; Xu ZL; Zhou TM; Ye B J Biol Regul Homeost Agents; 2017; 31(1):51-58. PubMed ID: 28337870 [TBL] [Abstract][Full Text] [Related]
53. Tamoxifen attenuates reactive astrocyte-induced brain metastasis and drug resistance through the IL-6/STAT3 signaling pathway. Xu Y; Zhu Y; Yue Y; Pu S; Wu J; Lv Y; Du D Acta Biochim Biophys Sin (Shanghai); 2020 Dec; 52(12):1299-1305. PubMed ID: 33355355 [TBL] [Abstract][Full Text] [Related]
54. Binding of galectin-1 to integrin β1 potentiates drug resistance by promoting survivin expression in breast cancer cells. Nam K; Son SH; Oh S; Jeon D; Kim H; Noh DY; Kim S; Shin I Oncotarget; 2017 May; 8(22):35804-35823. PubMed ID: 28415760 [TBL] [Abstract][Full Text] [Related]
55. Picrasidine G decreases viability of MDA-MB 468 EGFR-overexpressing triple-negative breast cancer cells through inhibition of EGFR/STAT3 signaling pathway. Yamashita N; Kondo M; Zhao S; Li W; Koike K; Nemoto K; Kanno Y Bioorg Med Chem Lett; 2017 Jun; 27(11):2608-2612. PubMed ID: 28427809 [TBL] [Abstract][Full Text] [Related]
56. Inhibition of basal-like breast cancer growth by FTY720 in combination with epidermal growth factor receptor kinase blockade. Martin JL; Julovi SM; Lin MZ; de Silva HC; Boyle FM; Baxter RC Breast Cancer Res; 2017 Aug; 19(1):90. PubMed ID: 28778177 [TBL] [Abstract][Full Text] [Related]
57. The anti-androgen drug dutasteride renders triple negative breast cancer cells more sensitive to chemotherapy via inhibition of HIF-1α-/VEGF-signaling. von Wahlde MK; Hülsewig C; Ruckert C; Götte M; Kiesel L; Bernemann C Gynecol Endocrinol; 2015 Feb; 31(2):160-4. PubMed ID: 25356777 [TBL] [Abstract][Full Text] [Related]
58. The targeted inhibition of Hsp90 by a synthetic small molecule, DPide offers an effective treatment strategy against TNBCs. Oh YJ; Park SY; Seo YH Oncol Rep; 2018 Apr; 39(4):1775-1782. PubMed ID: 29436674 [TBL] [Abstract][Full Text] [Related]
59. Thymoquinone inhibits cell proliferation, migration, and invasion by regulating the elongation factor 2 kinase (eEF-2K) signaling axis in triple-negative breast cancer. Kabil N; Bayraktar R; Kahraman N; Mokhlis HA; Calin GA; Lopez-Berestein G; Ozpolat B Breast Cancer Res Treat; 2018 Oct; 171(3):593-605. PubMed ID: 29971628 [TBL] [Abstract][Full Text] [Related]
60. Investigation of molecular alterations of AKT-3 in triple-negative breast cancer. O'Hurley G; Daly E; O'Grady A; Cummins R; Quinn C; Flanagan L; Pierce A; Fan Y; Lynn MA; Rafferty M; Fitzgerald D; Pontén F; Duffy MJ; Jirström K; Kay EW; Gallagher WM Histopathology; 2014 Apr; 64(5):660-70. PubMed ID: 24138071 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]